Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology - 19/06/24

Abstract |
Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome (PNP/PAMS) is a highly fatal autoimmune blistering disease. The condition occurs in patients with underlying benign or malignant neoplasms, most commonly lymphoproliferative disorders. Both humoral and cell-mediated immunities contribute to the pathogenesis, and autoantibodies against plakin family proteins are characteristic. Patients typically present with severe stomatitis and polymorphous skin lesions, which are often resistant to treatment. Bronchiolitis obliterans (BO) is a frequent complication which contributes to the high mortality rate of PNP/PAMS. Given the rarity of this disorder and heterogeneity of clinical presentation, clinicians should maintain a high index of suspicion for PNP/PAMS to avoid delayed diagnosis. In this first part of a two-part continuing medical education (CME) series, risk factors, pathogenesis, and clinical features of PNP/PAMS are discussed.
Le texte complet de cet article est disponible en PDF.Key words : bronchiolitis obliterans, Castleman disease, CLL, non-Hodgkin lymphoma, paraneoplastic, paraneoplastic autoimmune multiorgan syndrome, paraneoplastic pemphigus, pemphigus, plakin
Abbreviations used : A2ML1, BMZ, BO, BP, BPAG1, CLL, CME, CPI, CT, DIF, Dsg, ELISA, EM, GVHD, IIF, kDa, LP, MIRM/RIME, PAMS, PF, PNP, PV, SJS, TEN
Plan
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
|
| Patient consent: Not applicable. |
|
| Date of release: July 2024. |
|
| Expiration date: July 2027. |
Vol 91 - N° 1
P. 1-10 - juillet 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
